MSFT   181.42 (+0.01%)
FB   223.98 (-0.66%)
GOOGL   1,421.59 (+0.24%)
NVDA   342.16 (+0.79%)
BABA   197.22 (-1.14%)
MU   46.82 (+0.73%)
TSLA   811.39 (+0.69%)
T   30.65 (-1.32%)
ACB   14.03 (-8.54%)
F   5.75 (-1.71%)
DIS   116.41 (-0.29%)
BAC   24.81 (-0.20%)
BA   145.99 (-2.56%)
MSFT   181.42 (+0.01%)
FB   223.98 (-0.66%)
GOOGL   1,421.59 (+0.24%)
NVDA   342.16 (+0.79%)
BABA   197.22 (-1.14%)
MU   46.82 (+0.73%)
TSLA   811.39 (+0.69%)
T   30.65 (-1.32%)
ACB   14.03 (-8.54%)
F   5.75 (-1.71%)
DIS   116.41 (-0.29%)
BAC   24.81 (-0.20%)
BA   145.99 (-2.56%)
MSFT   181.42 (+0.01%)
FB   223.98 (-0.66%)
GOOGL   1,421.59 (+0.24%)
NVDA   342.16 (+0.79%)
BABA   197.22 (-1.14%)
MU   46.82 (+0.73%)
TSLA   811.39 (+0.69%)
T   30.65 (-1.32%)
ACB   14.03 (-8.54%)
F   5.75 (-1.71%)
DIS   116.41 (-0.29%)
BAC   24.81 (-0.20%)
BA   145.99 (-2.56%)
MSFT   181.42 (+0.01%)
FB   223.98 (-0.66%)
GOOGL   1,421.59 (+0.24%)
NVDA   342.16 (+0.79%)
BABA   197.22 (-1.14%)
MU   46.82 (+0.73%)
TSLA   811.39 (+0.69%)
T   30.65 (-1.32%)
ACB   14.03 (-8.54%)
F   5.75 (-1.71%)
DIS   116.41 (-0.29%)
BAC   24.81 (-0.20%)
BA   145.99 (-2.56%)
Log in

NASDAQ:PRVLPrevail Therapeutics Stock Price, Forecast & News

$16.85
-0.04 (-0.24 %)
(As of 05/29/2020 10:28 AM ET)
Add
Compare
Today's Range
$16.60
Now: $16.85
$17.12
50-Day Range
$12.36
MA: $15.31
$18.20
52-Week Range
$7.41
Now: $16.85
$19.96
Volume600 shs
Average Volume154,568 shs
Market Capitalization$576.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. The company was founded in 2017 and is based in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRVL
CUSIPN/A
CIKN/A
Phone917-336-9310

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.34 per share

Profitability

Net Income$-63,190,000.00

Miscellaneous

Employees33
Market Cap$576.27 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive PRVL News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVL and its competitors with MarketBeat's FREE daily newsletter.

Prevail Therapeutics (NASDAQ:PRVL) Frequently Asked Questions

How has Prevail Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Prevail Therapeutics' stock was trading at $12.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRVL stock has increased by 34.4% and is now trading at $16.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Prevail Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prevail Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Prevail Therapeutics.

When is Prevail Therapeutics' next earnings date?

Prevail Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Prevail Therapeutics.

How were Prevail Therapeutics' earnings last quarter?

Prevail Therapeutics Inc. (NASDAQ:PRVL) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.06. View Prevail Therapeutics' earnings history.

What price target have analysts set for PRVL?

7 Wall Street analysts have issued 1-year price objectives for Prevail Therapeutics' stock. Their forecasts range from $15.00 to $25.00. On average, they expect Prevail Therapeutics' share price to reach $21.00 in the next year. This suggests a possible upside of 24.6% from the stock's current price. View analysts' price targets for Prevail Therapeutics.

Has Prevail Therapeutics been receiving favorable news coverage?

Press coverage about PRVL stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prevail Therapeutics earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutPrevail Therapeutics.

Are investors shorting Prevail Therapeutics?

Prevail Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the March 31st total of 1,120,000 shares. Based on an average daily volume of 148,300 shares, the days-to-cover ratio is presently 8.2 days. Approximately 4.4% of the shares of the company are short sold. View Prevail Therapeutics' Current Options Chain.

Who are some of Prevail Therapeutics' key competitors?

What other stocks do shareholders of Prevail Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Editas Medicine (EDIT), AbbVie (ABBV), Alector (ALEC), Crispr Therapeutics (CRSP), Gossamer Bio (GOSS), Stoke Therapeutics (STOK), TG Therapeutics (TGTX), Atreca (BCEL), Gilead Sciences (GILD) and Myovant Sciences (MYOV).

Who are Prevail Therapeutics' key executives?

Prevail Therapeutics' management team includes the following people:
  • Dr. Asa Abeliovich M.D., Ph.D., Founder, Pres, CEO & Director (Age 55)
  • Dr. Brett Kaplan M.D., Chief Financial Officer (Age 45)
  • Dr. Yong Dai, Chief Technology Officer (Age 48)
  • Ms. Emily Minkow, Chief Bus. Officer (Age 36)
  • Dr. Franz F. Hefti Ph.D., Chief Devel. Officer (Age 71)

When did Prevail Therapeutics IPO?

(PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Prevail Therapeutics' stock symbol?

Prevail Therapeutics trades on the NASDAQ under the ticker symbol "PRVL."

Who are Prevail Therapeutics' major shareholders?

Prevail Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.47%), BlackRock Inc. (3.32%), Bank of New York Mellon Corp (0.66%), State Street Corp (0.61%), Geode Capital Management LLC (0.45%) and QVT Financial LP (0.39%). View institutional ownership trends for Prevail Therapeutics.

Which institutional investors are selling Prevail Therapeutics stock?

PRVL stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Squarepoint Ops LLC, and UBS Group AG. View insider buying and selling activity for Prevail Therapeutics.

Which institutional investors are buying Prevail Therapeutics stock?

PRVL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., QVT Financial LP, State Street Corp, Morgan Stanley, Geode Capital Management LLC, Nuveen Asset Management LLC, Two Sigma Investments LP, and JPMorgan Chase & Co.. View insider buying and selling activity for Prevail Therapeutics.

How do I buy shares of Prevail Therapeutics?

Shares of PRVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prevail Therapeutics' stock price today?

One share of PRVL stock can currently be purchased for approximately $16.85.

How big of a company is Prevail Therapeutics?

Prevail Therapeutics has a market capitalization of $576.27 million. The company earns $-63,190,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Prevail Therapeutics employs 33 workers across the globe.

What is Prevail Therapeutics' official website?

The official website for Prevail Therapeutics is www.prevailtherapeutics.com.

How can I contact Prevail Therapeutics?

Prevail Therapeutics' mailing address is 430 East 29th Street Suite 1520, New York NY, 10016. The company can be reached via phone at 917-336-9310 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.